Provides life reinsurance solutions to insurance companies. Offers health reinsurance products to manage healthcare-related risks. Now — the numbers.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
The market pays 10.8× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 9% a year on average.
It pays out $1.44 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.